| 565 ETTENGER ET al.
On September 27, 2016 , the Food and Drug Administration (FDA) held a public meeting for the FDA to hear from organ trans- The panel participants were identified by the FDA to represent a range of perspectives. Panel comments were followed by largegroup facilitated discussions involving the audience as well as online attendees.
| MEETING OVERVIEW
In the afternoon, a panel of experts presented a scientific session on medication adherence and interventions to mitigate nonadherence.
This was followed by a facilitated discussion of approaches to management of transplantation, with participation by patients, academic and industry experts, healthcare providers, government officials, and advocacy organizations.
| REPORT OVERVIEW AND KEY THEMES
Despite the aforementioned diversity, participants provided consistent input with a rich depiction of benefits but also challenges, highlighting their emotional, physical, and social burdens as transplant recipients. Several key themes emerged from this meeting.
1.
Participants broadly credited their transplants with having a transformative effect on their overall health.
2.
While recognizing the benefits of their transplant, participants identified significant serious, chronic, and burdensome health effects in their posttransplant lives; even those who had not experienced these health effects directly described them as their biggest concerns for the future. Participants also described emotional impacts including depression and constant anxiety about infection and rejection.
3.
While acknowledging the importance their immunosuppressive therapy (IST), many experienced burdens due to their complex treatment regimens, including difficulties with side effects and frequent monitoring, testing, and clinic visits.
4.
Adherence to treatment regimens is a significant challenge for transplant recipients; the IST regimens were described as complex and strict. Adherence is also affected by the burden of IST side effects.
| TOPIC 1: PATIENT PERSPECTIVES ON POSTTRANSPLANT HEALTH EFFECTS
Patients acknowledged that transplants prolong and enrich lives; avoid or reduce the need for burdensome treatments for the initial disease condition; relieve pain and fatigue; and facilitate physical and social activities. Younger participants and parents described a return to a near-normal daily life.
While acknowledging these benefits, patients indicated that they exchanged 1 set of challenges for another, highlighting such problems as:
1.
Cancer: Most participants identified the risk of cancer as one of their most worrisome long-term health concerns, and one that caused significant anxiety.
Graft rejection:
While only a few of the attendees experienced rejection personally (and those who did found it an "intense struggle"), most identified it as being one of their biggest concerns for their future health. Participants realized that the options for those who rejected their organs were limited to either getting another organ or dying.
3.
Infection: Participants acknowledged that they were more susceptible to common infections with slower recovery and more severe sequelae.
Other problems mentioned were gastrointestinal issues, vision problems, diabetes mellitus, fatigue, hearing loss, pain, sleep disturbances, cognitive impacts (inability to focus or think clearly), and dietary challenges. Participants expressed difficulty distinguishing whether burdensome symptoms were related to their transplant, their underlying health condition, or their medications.
| Emotional impacts and concerns for the future
The 
| Burdens of managing day-to-day life
Participants described difficulties with the reality of daily posttransplant life, such as being overly concerned about even small illnesses.
They indicated that skin care and dietary needs (eg, necessity for large fluid intake, maintaining a healthy weight, being vigilant about food hygiene) represented significant personal care challenges. Other bothersome problems were neurologic/cognitive and included insomnia and inability to concentrate. Participants also acknowledged social impacts of their transplant status. They described having an organ transplant as having an "invisible disease," and encountered a lack of understanding when requesting special accommodations because they "didn't appear sick." Some participants also reported an inability to participate in physical activities because of fatigue and a lack of stamina.
| TOPIC 2: PATIENTS' PERSPECTIVES ON TRANSPLANT AND TREATMENT IMPACTS
This session addressed participants' views and concerns about their experiences with IST. Most acknowledged that IST was critical in maintaining the health of their transplant, accepting that IST's benefits outweighed the adverse effects. Almost all were receiving calcineurin inhibitors and glucocorticoids, while approximately 75% were using antimetabolite purine antagonists. Twenty percent were receiving mammalian target of rapamycin inhibitors, and a small number were on belatacept. Of note, 40% reported using opioids, 20% were receiving antidepressants, and over 50% were taking other prescription drugs such as antibiotics, antivirals, antihypertensives, lipid-lowering agents,
and pain medications such as nonsteroidal anti-inflammatory agents.
| Treatment downsides
Participants acknowledged the challenges finding a treatment regimen that worked for them, and emphasized the demands and shortcomings of IST. While some expressed satisfaction with both the result of their ISTs and the lack of side effects, many others faced significant difficulties in finding a regimen that worked for them. Challenges included the following: 
| Adherence
Throughout the meeting (see below), participants discussed their perspectives on the importance of adhering to a consistent IST regimen, their difficulties with adherence, and their thoughts about improving adherence. Challenges to adherence included the following:
Frequency and high amounts of ISTs

Coordinating medication with diet
Burdens of clinic visits and monitoring
Impact of side effects
Remembering to take their ISTs promptly
Perspectives on improving adherence included reducing the number of daily treatments and improving communication on the importance of adherence, especially to pediatric transplant recipients.
| Perspectives on ideal treatments for organ transplantation
Participants discussed ideal attributes of ISTs. They identified a need for therapies that would provide long-term protection for the transplant; not harm the organ; have fewer long-term side effects and fewer risks, such as cancer and infection; and reduce the frequency of medication administration. They also expressed that even if an IST met their needs, they were not always confident about the equivalence of brand and generic versions of the treatment, and they were concerned that they were often switched from a brand to a generic version for insurance reasons, without their prescriber's knowledge. Additionally, participants noted the contradictory message healthcare systems sent regarding adherence, noting that often when they were hospitalized, healthcare systems were frequently "nonadherent" with respect to providing IST on a correctly timed administration schedule. Similar concerns were expressed about undergoing procedures and clinic appointment schedules.
| PATIENT PERSPECTIVE CAN INFORM DRUG DEVELOPMENT AND DRUG EVALUATION
The patient input generated through this Patient-Focused Drug to the drug development process more broadly, such as to IST developers, as they explore treatments for more organ-specific targeted therapies or in designing interventions that facilitate patient adherence.
FDA recognizes the need to provide guidance to facilitate the advancement and use of methodologically sound approaches to collect and utilize robust and meaningful patient and caregiver input that can inform drug development, and, as appropriate, regulatory decision making. FDA will work to advance the science and provide this guidance over the coming years. Nevertheless, patients experience graft loss at 5%-6% per year. In a Winnipeg cohort, 75% of patients maintain stable graft function through 15 years. 3 Consistent with the report from the Mayo Clinic, graft failure primarily was related to de novo donor-specific antibodies (DSA) directed against mismatched human leukocyte antigens (HLA), 4 particularly Class II antigens, 5 resulting in antibody-mediated rejection (AMR) episodes, the majority of which were subclinical. 4 The overall incidence of de novo DSA varies from 7% to 27%, depending in part on the length of time in which the patients were studied. [6] [7] [8] [9] The annual incidence of de novo DSA varies from as low as
| SCIENTIFIC SESSION: MEDICATION ADHERENCE AND EXPERIENCE WITH INTERVENTION
1.3%-2% to as high as 5.1%-8.2% per year, 4,6,7-9 depending on the length of follow-up. Numerous studies show that early T cell-mediated rejection (TCMR) is linked to subsequent de novo DSAs, [10] [11] [12] [13] which in turn are strongly linked to acute and chronic AMR with resultant graft dysfunction and loss. [6] [7] [8] 14 An important contributor is under-immunosuppression, whether due to a clinically necessary decision to lower IST to minimize side effects or IST complications
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(eg, to deal with a severe infection) or to medication nonadherence. suggested that more precise molecular matching (eg, eplet) for Class II antigens may allow for lower tacrolimus levels to be used without the generation of de novo Class II DSA. 16 While more studies are necessary, these data suggest that improved HLA matching (especially Class II eplet matching) and the avoidance of inappropriate underimmunosuppression/medication nonadherence may lead to fewer de novo DSA and improved long-term graft outcome.
| Dr. Rita Alloway: exploring nonadherence in solid organ transplant recipients
Medication adherence describes the extent to which patients take medications as prescribed. 17 Nonadherence can be intentional or unintentional. Transplant-specific factors for medication nonadherence and their potential capacity for modification are outlined in Table 1 .
Measurement of medication adherence remains challenging.
Objective direct measures are highly reliable, but are expensive and impractical. Indirect measures (eg, pill counts or pharmacy refill records) are objective, noninvasive, and inexpensive. 18 However, results
can be misinterpreted with frequent dosing changes, especially when prescriptions are filled at multiple pharmacies.
Electronic monitoring (EM) can wirelessly record, document, and alert the provider when the pill container is opened. 19 While objective and noninvasive, EM is expensive. Multidrug pill boxes with EM are optimal but bulky, and opening the EM device is only a surrogate for pill consumption.
An increasingly popular direct measure is tacrolimus trough level variability over time. High variability is associated with a variety of negative posttransplant outcomes, eg, acute rejection and transplant glomerulopathy.
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Subjective measures rely on testimony that the drug has been taken. These are simple and noninvasive, but are unreliable because patients often overestimate their adherence. 21 Similarly, clinician reports underestimate nonadherence. 22 While there is no ideal single measure, using multiple measures in tandem ("triangulation") best assesses adherence. Thus, some patients demonstrate vigilant medication-taking (by, for example, using reminders, being willing to tolerate side effects, or wanting to show gratitude). Other patients show considerable medication nonadherence due to factors such as forgetfulness, side effects, and cost. A third group-probably the largest-shows partial adherence due to mixed success at managing these factors. 
| Dr. Mary Amanda Dew: prevalence of nonadherence after organ transplantation
| Dr. Robert Ettenger: adherence to immunosuppressive medications in pediatric and adolescent transplant recipients
Kidney transplant recipients in their late teens and early 20s are at the greatest risk for allograft failure, in large part due to IST nonadherence. 28 The assessment of medication nonadherence in pediatric recipients is challenging because studies utilize variations in measurement methodology, definitions of nonadherence, and the proportion of patients in various age groups. All studies agree that nonadherence is greatest in adolescence. Kidney transplant recipients ≤10 years old have a 22% rate of nonadherence, while patients >10 years old have a rate of 43%. 29 Pediatric patients have unique characteristics that impact nonadherence (Table 2 ), but many of these are difficult to modify. Adolescence is a time of unique psychosocial and developmental changes: emotional (limbic) circuitry develops earlier than the neurocognitive (prefrontal) activity necessary for executive functioning (eg, planning, reasoning), critical for self-care and adherence. Simultaneously, adolescence is a time of individuation and questioning authority.
Scales are available to measure adolescents' adherence barriers. The most frequent barriers are those that reflect forgetfulness/ distraction and poor planning. 30 Barriers reflecting disorganization/ not planning ahead and the desire to avoid being observed taking IST are directly related to nonadherence and emotional distress. 31 A high number of such barriers is a sensitive indicator of nonadherence risk.
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While the medical team may recognize these barriers, correlations are imprecise, and preventive measures to forestall nonadherence are at best inexact. Drug level variability is highly correlated with rejection and de novo DSA in pediatric recipients, 33, 34 and it may be possible to use this measure to try to modify behavior before it results in these adverse outcomes, but as with other measurements currently available, it remains difficult to identify with certainty who is at risk because we do not know, on an individual basis, how much nonadherence is "enough" to be deleterious.
| Open discussion of scientific discussion 1: causes of late allograft loss and the impact of nonadherence, definitions, terms, and background
A major topic was the difficulty in defining the critical level of adherence. In many ways, transplant recipients are different from patients with other illnesses that require chronic self-medication. In such conditions as HIV or diabetes mellitus, there are clinical indices/laboratory studies (eg, CD4+ cell counts for HIV, hemoglobin A1C for diabetes mellitus) that can measure whether medication adherence is "sufficient" to control the disease process. For transplant recipients, on the other hand, the only readily available "biomarkers" for treatment adequacy reflect organ damage (eg, elevated serum creatinine in renal transplant recipients). These currently available "biomarkers" often may only become manifest when it is too late to totally repair damage done by insufficient immunosuppression. Thus, the medical team is less able to "titrate" IST dosage or adequacy of adherence than in other conditions.
Most patients acknowledged that 100% adherence is rare, and so most patients make their own determinations as to what is tolerable for missing medications, taking medications on an empty stomach, and the exact timing of ingestion. Patients correctly observe that different levels of adherence are tolerated differently in different patients.
However, they note that medical personnel adopt a "one size fits all" mandate for 100% adherence. Several participants felt that healthcare providers were too overbearing about IST adherence. This entire ques- Several interventions have focused on medication adherence, 36, 37 while others considered adherence to multiple components of care. 38, 39 Education alone was ineffective. In a multicomponent website, more frequent use of the adherence-focused component (assisting patients with new management strategies) led to improved heart recipient adherence. 38 A smartphone app, Pocket PATH, gives lung recipients tools to monitor their self-care, including IST adherence. increased self-monitoring and overall regimen adherence. 39 Patients who benefited from Pocket PATH in the first year showed lower mortality risk at 6 years posttransplant. 39 A version has been adapted and field-tested in adolescents. 40 In liver recipients, an RCT of face-to-face pharmacist-led education and quarterly monitoring sessions over 1 year found that the intervention group had better dosing adherence and higher rates of target IST levels.
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A recent RCT tested a bimonthly face-to-face multicomponent intervention over a 6-month period 37 
| Dr. Marie Chisholm-Burns: interventions to improve adherence among adult renal transplant recipients
Two examples of multimodal interventions in adult kidney recipients illustrate the success of empowering patients towards self-efficacy in adherence. The first was an RCT of behavioral contracting involving the development of a patient-specific, written agreement between patients in multiple states and pharmacists. 41 Over 12 months, patients negotiated behavioral contracts with a pharmacist on a quarterly basis, addressing adherence barriers and individualized solutions, consequences of nonadherence, and motivations, and social support to achieve adherence. Such behavioral contracting resulted in significantly higher and durable adherence rates at all time points after 6 months, with a reduction in subsequent hospitalizations and significant cost savings. 41 The second RCT of a clinical pharmacy services intervention occurred during the first year posttransplant. 42 A clinical pharmacist reviewed medications, emphasizing therapy optimization and minimization of adverse side effects. The pharmacist also increased recipients' access to IST by enrolling them into manufacturers' assistance programs. During the 12-month study period, the mean adherence rate improved significantly, never falling below 90%. Recipients also had a significantly longer duration of adherence and were more likely to achieve "target" IST concentrations. Medication costs were significantly reduced. These trials strongly suggest that individualized interventions can improve IST adherence in kidney transplantation. Challenges remain in identifying appropriate resources to maintain such individualized methods over the long term.
| Dr. Robert Ettenger: interventions to improve medication adherence and outcomes in adolescent transplant recipients
Because adolescents are continually experiencing different developmental stages, individualized interventions are necessary. As adolescents are concerned with the "here and now," they will benefit most from interventions that provide immediate feedback and incentives.
However, such interventions are resource intensive and thus difficult to sustain.
Principles that can help adolescents achieve IST adherence are outlined in Table 3 . Education is important in families with difficulty in transferring responsibility from parents to adolescents, 43 but education alone is insufficient to sustain adherence. [44] [45] [46] Multicomponent interventions that include behavioral change in such chronic childhood conditions as asthma, diabetes mellitus, and HIV have the highest effectiveness, 46 ,47 but without reinforcement, adherence can dissipate over time. 48, 49 A large recently completed 12-month multicenter RCT with multicomponent interventions 50 showed that intervention recipients had a 50% higher likelihood of perfect taking-adherence relative to controls. 51 Other promising interventions have included the use of mHealth text messaging, 52, 53 and the identification and treatment of posttraumatic stress disorder. 54 Finally, it has been recognized that transfer to adult-centered care is associated with worsening clinical outcomes, 51, 55 due mainly to medication nonadherence. 56 A number of interventions and assessment tools have been designed to help ameliorate this problem. [57] [58] [59] All of the successful interventions in pediatrics must be individualized, and become resource intensive over the long life of a pediatric organ transplant.
T A B L E 3 Minimal practical guidelines on which to build successful adherence intervention in adolescent transplant recipients Medical team's communication with patient/family -Interactional model rather than a we/they approach -Nonjudgmental-avoid selective attribution of blaming the patient -Team approach-patients, parents, and healthcare providers are considered a team -Build personal chemistry-different healthcare providers connect better with each individual patient Posttransplant interventions to forestall nonadherence -Continual education with each clinic visit -Use additional tools to achieve multimodal intervention: eg, behavioral therapy, psychological counseling, identifying emotional or social difficulties -Recognize that for any given individual, medication adherence behavior can change dramatically -Clinic visits often need to be more frequent than in young children or adults to provide continual reinforcement even years after transplantation -Encourage organizational self-care skills: eg, organized pillboxes, written postclinic instructions, using smartphone apps to document medication administration -Address new-onset patient or parent new-onset psychological or social distress promptly and as completely as possible (7) The need for long-term daily IST creates a negative stigma and reminds the recipients that they are "sick"; such stigmata may ultimately lead to burnout and depression. There was a general consensus by transplant recipients that addressing these issues would improve outcomes.
| CONCLUSIONS
The life-transforming effects of organ transplantation cannot be denied, but the discussions at this meeting focused heavily on the challenges recipients face with their long-term ongoing healthcare. 
